Lenalidomide (LDM)
Lenalidomide is one of the novel drug agents used to treat multiple myeloma. It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor secreted cytokines and tumor proliferation through the induction of apoptosis.Compared to placebo, lenalidomide is effective in induring complete or "very good partial" response, and progression-free survival is improved. Adverse events more common in people receiving lenalidomide for myeloma were neutropenia (a decrease in the white blood cell count), deep vein thrombosis, infections, and an increased risk of other hematological malignancies. The risk of second primary hematological malignancies does not outweigh the benefit of using lenalidomide in relapsed or refractory multiple myeloma. It may be more difficult to mobilize stem cells for autograft in people who have received lenalidomide.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Lenalidomide (LDM) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Lenalidomide (LDM) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Lenalidomide (LDM) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Lenalidomide (LDM) CLIA Kit Customized Service Offer
n/a ELISA Kit for Lenalidomide (LDM) ELISA Kit Customized Service Offer